Chimeric Polypeptide Transdermal Delivery via Zinc Finger Fusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively deliver botulinum toxins (BoNTs) transdermally due to the skin's barrier properties, and existing BoNT compositions face challenges such as pain, needle marks, and bruising, especially in thin skin areas like the crow's feet or lateral canthus regions.
Innovation Solution
A chimeric polypeptide comprising a botulinum toxin light chain fused with a zinc finger motif, either on the same peptide chain or as separate chains connected by a disulfide bond, which allows for transdermal delivery by penetrating the skin, potentially reducing the need for invasive injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional injection methods are used to deliver BoNTs, then therapeutic effect is achieved, but pain, needle marks, and bruising occur
Solution Approach 1:
The patent replaces the mechanical injection system with a chemical formulation system. The chimeric polypeptide combines BoNT with cell-penetrating peptide sequences that facilitate transdermal delivery through chemical mechanisms rather than mechanical needles, eliminating injection-related trauma while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces cell-penetrating peptide sequences as intermediary molecules that mediate the delivery of BoNT across the skin barrier. These peptides act as carriers that facilitate transdermal penetration without requiring direct mechanical penetration, thus reducing pain and bruising while ensuring therapeutic delivery.
2Reliability
If multiple injections are used to achieve maximum effects, then therapeutic efficacy is improved, but patient comfort and ease of application deteriorate
Solution Approach 1:
The patent merges multiple therapeutic functions into a single chimeric polypeptide molecule. By combining BoNT with cell-penetrating peptide sequences in one unified structure, the formulation achieves maximum therapeutic effect through a single application rather than multiple injections, thereby improving patient comfort and ease of use.
3Ease of operation
If BoNT is applied topically without penetration enhancement, then simplicity of application is maintained, but skin barrier prevents effective delivery
Solution Approach 1:
The patent changes the molecular parameters of the BoNT formulation by attaching cell-penetrating peptide sequences to the BoNT molecule. This parameter change enables the formulation to overcome the skin barrier through transdermal penetration while maintaining the simplicity of topical application, as the modified BoNT naturally penetrates skin cells without requiring complex delivery devices.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion of BoNT with zinc finger motifs enables efficient skin penetration and maintains enzymatic activity, achieving muscle paralysis similar to injected BoNTs when applied topically, with improved expression and purification yields compared to traditional cell penetration peptides.
Implementation Method 1
A chimeric polypeptide comprising a botulinum toxin light chain fused with a zinc finger motif, either on the same peptide chain or as separate chains connected by a disulfide bond, which allows for transdermal delivery by penetrating the skin
Implementation Method 2
a chimeric polypeptide comprising (a) a botulinum toxin (BoNT) light chain and (b) a first zinc finger motif located to the C-terminal of the BoNT light chain or located to the C-terminal to a BoNT heavy chain which is located C-terminal to the BoNT light chain or bound to the BoNT light chain through a disulfide bond
Implementation Method 3
The light chain of botulinum is a metalloprotease that specifically cleaves SNARE (soluble N-ethylmaleimide-sensitive fusion attachment protein receptor) complex proteins
Data Source
AI summary
The present disclosure provides chimeric polypeptides that include one or more zinc finger motif fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It is shown that the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally.